China's Growing Control Over US Pharmaceutical Supply Chain

The report warns that the United States is increasingly reliant on China for critical active pharmaceutical ingredients—China supplied 39.9% of U.S. API imports in 2024 and controls 99% of some essential inputs—creating a national security risk where access to medicines could become a geopolitical bargaining chip; it also notes U.S. regulatory practices and clinical trials in China may accelerate Chinese pharmaceutical capabilities.